Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01811225 · ClinicalTrials.gov registry record · Phase 2
Smoking, Sex Hormones, and Pregnancy
A Phase 2 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
NCT01811225 is a Phase 2 study that has completed, run by University of Minnesota. The registered enrollment target is 95 participants.
The verdict
NCT01811225, a Phase 2 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
Study Summary
The investigators aim to (1) examine the association between levels of progesterone (Prog), allopregnanolone (Allo), and the estradiol/progesterone (E2/P) ratios with smoking-related symptomatology during ad libitum smoking and (2) determine the association between Prog, Allo, and E2/P with the changes in smoking-related symptomatology and response to nicotine following overnight abstinence
Interventions
- DRUG Low-dose Progesterone
- DRUG High-dose Progesterone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2012-12 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01811225
The ClinicalTrials.gov registry entry for NCT01811225 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Low-dose Progesterone is the first listed.
NCT01811225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01811225 about?
NCT01811225 is a clinical study titled "Smoking, Sex Hormones, and Pregnancy". The investigators aim to (1) examine the association between levels of progesterone (Prog), allopregnanolone (Allo), and the estradiol/progesterone (E2/P) ratios with smoking-related symptomatology during ad libitum smoking and (2) determine the association between Prog, Allo, and E2/P with the chan...
What is the current status of trial NCT01811225?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 2012-12. Estimated completion is 2017-06.
What interventions are being tested in trial NCT01811225?
The interventions under investigation include: Low-dose Progesterone (DRUG), High-dose Progesterone (DRUG).
Who is sponsoring clinical trial NCT01811225?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.